fbpx

News:  Plus Therapeutics Announces Plans for Treating Pediatric Brain Cancer

Pediatric Brain Cancer:
U.S. Phase 1 Clinical Trial

 

Not Yet Recruiting

Pediatric Brain
Cancer:  U.S. Phase
1 Clinical Trial

 

Not Yet Recruiting

Pediatric
Brain
Cancer:
U.S. Phase
1 Clinical
Trial

 

Not Yet Recruiting

Trial Information

Cancer is the leading cause of death by disease among children in the U.S.  Brain and spinal cord tumors are the 2nd most common cancers in children, accounting for ~26% of childhood cancers.

Plus Therapeutics is developing the 186RNL radiotherapeutic for the treatment of rare, frequently fast-growing pediatric brain and spinal cord tumors with a poor prognosis – diffuse instrinsic pontine glioma (DIPG), ependymoma and high-grade glioma (HGG).  The ReSPECT™-PBC (Pediatric Brain Cancer) U.S. Phase 1 Clinical Trial is planned to initiate in 2022.

“Children with brain tumors have limited options & 186RNL delivered with a minimally invasive procedure could be an important new potential option for these patients.”

Michael G. DeCuypere, MD, PhD, FAANS

Northwestern University Feinberg School of Medicine

What Can You Do Next?

Participating in a clinical trial is an important decision.  If you believe this clinical trial might be a good fit and are interested in participating, please take the next step to see if you are eligible.

Request Information

2 + 15 =